Literature DB >> 22609287

Pulsed high-intensity-focused US and tissue plasminogen activator (TPA) versus TPA alone for thrombolysis of occluded bypass graft in swine.

Nadine Abi-Jaoudeh1, William F Pritchard, Hayet Amalou, Marius Linguraru, Oscar A Chiesa, Joshua D Adams, Carmen Gacchina, Robert Wesley, Subha Maruvada, Briana McDowell, Victor Frenkel, John W Karanian, Bradford J Wood.   

Abstract

PURPOSE: Prosthetic arteriovenous or arterial-arterial bypass grafts can thrombose and be resistant to revascularization. A thrombosed bypass graft model was created to evaluate the potential therapeutic enhancement and safety profile of pulsed high-intensity-focused ultrasound (pHIFU) on pharmaceutical thrombolysis.
MATERIALS AND METHODS: In swine, a right carotid-carotid expanded polytetrafluoroethylene bypass graft was surgically constructed, containing a 40% stenosis at its distal end to induce graft thrombosis. The revascularization procedure was performed 7 days after surgery. After model development and dose response experiments (n = 11), two cohorts were studied: pHIFU with tissue plasminogen activator (TPA; n = 4) and sham pHIFU with TPA (n = 3). The experiments were identical in both groups except no energy was delivered in the sham pHIFU group. Serial angiograms were obtained in all cases. The area of graft opacified by contrast medium on angiograms was quantified with digital image processing software. A blinded reviewer calculated the change in the graft area opacified by contrast medium and expressed it as a percentage, representing percentage of thrombolysis.
RESULTS: Combining pHIFU with 0.5 mg of TPA resulted in a 52% ± 4% increase in thrombolysis on angiograms obtained at 30 minutes, compared with a 9% ± 14% increase with sham pHIFU and 0.5 mg TPA (P = .003). Histopathologic examination demonstrated no differences between the groups.
CONCLUSIONS: Thrombolysis of occluded bypass grafts was significantly increased when combining pHIFU and TPA versus sham pHIFU and TPA. These results suggest that application of pHIFU may augment thrombolysis with a reduced time and dose.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609287      PMCID: PMC3511867          DOI: 10.1016/j.jvir.2012.04.001

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  35 in total

1.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes; Kevin Bell; Joseph Caporusso; Isabelle Durand-Zaleski; Kimihiro Komori; Johannes Lammer; Christos Liapis; Salvatore Novo; Mahmood Razavi; Johns Robbs; Nicholaas Schaper; Hiroshi Shigematsu; Marc Sapoval; Christopher White; John White; Denis Clement; Mark Creager; Michael Jaff; Emile Mohler; Robert B Rutherford; Peter Sheehan; Henrik Sillesen; Kenneth Rosenfield
Journal:  Eur J Vasc Endovasc Surg       Date:  2006-11-29       Impact factor: 7.069

Review 2.  The role of established and emerging risk factors in peripheral vascular graft occlusion.

Authors:  E M Fatourou; K I Paraskevas; A M Seifalian; G Hamilton; D P Mikhailidis
Journal:  Expert Opin Pharmacother       Date:  2007-05       Impact factor: 3.889

Review 3.  Ultrasound thrombolysis.

Authors:  Robert J Siegel; Huai Luo
Journal:  Ultrasonics       Date:  2008-03-28       Impact factor: 2.890

Review 4.  Modified prosthetic vascular conduits.

Authors:  Muneera R Kapadia; Daniel A Popowich; Melina R Kibbe
Journal:  Circulation       Date:  2008-04-08       Impact factor: 29.690

5.  Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity.

Authors:  F A Weaver; A J Comerota; M Youngblood; J Froehlich; J D Hosking; G Papanicolaou
Journal:  J Vasc Surg       Date:  1996-10       Impact factor: 4.268

6.  Ultrasound-enhanced Thrombolysis.

Authors:  Amir Motarjeme
Journal:  J Endovasc Ther       Date:  2007-04       Impact factor: 3.487

7.  Pulsed-high intensity focused ultrasound enhanced tPA mediated thrombolysis in a novel in vivo clot model, a pilot study.

Authors:  Michael J Stone; Victor Frenkel; Sergio Dromi; Peter Thomas; Ryan P Lewis; King C P Li; McDonald Horne; Bradford J Wood
Journal:  Thromb Res       Date:  2007-05-04       Impact factor: 3.944

8.  Pulsed high-intensity focused ultrasound enhances thrombolysis in an in vitro model.

Authors:  Victor Frenkel; Jay Oberoi; Michael J Stone; Melissa Park; Cheri Deng; Bradford J Wood; Ziv Neeman; McDonald Horne; King C P Li
Journal:  Radiology       Date:  2006-02-21       Impact factor: 11.105

9.  Dissolution of thrombotic arterial occlusion by high intensity, low frequency ultrasound and dodecafluoropentane emulsion: an in vitro and in vivo study.

Authors:  T Nishioka; H Luo; M C Fishbein; B Cercek; J S Forrester; C J Kim; H Berglund; R J Siegel
Journal:  J Am Coll Cardiol       Date:  1997-08       Impact factor: 24.094

10.  Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure.

Authors:  Victor Frenkel; Amena Etherington; Maiya Greene; Jade Quijano; Jianwu Xie; Finie Hunter; Sergio Dromi; King C P Li
Journal:  Acad Radiol       Date:  2006-04       Impact factor: 3.173

View more
  2 in total

1.  Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease.

Authors:  Paul S Fishman; Victor Frenkel
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

2.  MR-guided transcranial focused ultrasound safely enhances interstitial dispersion of large polymeric nanoparticles in the living brain.

Authors:  David S Hersh; Pavlos Anastasiadis; Ali Mohammadabadi; Ben A Nguyen; Sijia Guo; Jeffrey A Winkles; Anthony J Kim; Rao Gullapalli; Asaf Keller; Victor Frenkel; Graeme F Woodworth
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.